Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study

Journal of Clinical Oncology

Volumn 23, Issue 25, 2005, Pages 5960-5972

  Leyland Jones, Brian ^a   Semiglazov, Vladimir ^b   Pawlicki, Marek ^b   Pienkowski, Tadeusz ^b   Tjulandin, Sergei ^b   Manikhas, George ^b   Makhson, Antoly ^b   Roth, Anton ^b   Dodwell, David ^b   Baselga, Jose ^b   Biakhov, Mikhail ^b   Valuckas, Konstantinas ^b   Voznyi, Edouard ^b   Liu, Xiangyang ^b   Vercammen, Els ^b  

^a MCGILL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; HEMOGLOBIN; LETROZOLE; METHOTREXATE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN; TAXANE DERIVATIVE; ANTIANEMIC AGENT;

ADULT; ANEMIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; BREAST TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; BREAST NEOPLASMS; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; NEOPLASM METASTASIS; PLACEBOS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 24944454286     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.150     Document Type: Article

References (40)

1. Littlewood TJ, Bajetta E, Mortier JWR, et al, for the Epoetin Alfa Study Group: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
2. Dammacco F, Castoldi G, Rödjer S: Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172-179, 2001
3. Abels RI: Recombinant human erythropoietin in the treatment of anaemia of cancer. Acta Haematol 87:4-11, 1992 (suppl 1)
4. Demetri GD, Kris M, Wade J, et al, for the Procrit Study Group: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 16:3412-3425, 1998
5. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882, 2001
6. Glaspy J, Bukowski R, Steinberg D, et al, for the Procrit Study Group: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218-1234, 1997
7. Cella D, Zagari MJ, Vandoros C, et al: Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 21:366-373, 2003
8. Patrick DL, Gagnon DD, Zagari MJ, et al, for the Epoetin Alfa Study Group: Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 39:335-345, 2003
9. Fallowfield L, Gagnon D, Zagari M, et al, for the Epoetin Alfa Study Group: Multivariate regression analyses of data from a randomized, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 87:1341-1353, 2002
10. Caro JJ, Salas M, Ward A, et al: Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 91:2214-2221, 2001
11. Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991
12. Bokemeyer C, Oechsle K, Hartmann JT, et al: Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer 87:1066-1071, 2002
13. Casas F, Viñolas N, Ferrer F, et al: Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 55:116-124, 2003
14. Fein DA, Lee WR, Hanlon AL, et al: Pre-treatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 13:2077-2083, 1995
15. Glaser CM, Millesi W, Kornek GV, et al: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50:705-715, 2001
16. Grogan M, Thomas GM, Melamed I, et al: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86:1528-1536, 1999
17. MacRae R, Shyr Y, Johnson D, et al: Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 64:37-40, 2002
18. Schafer U, Micke O, Muller SB1 et al: Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 179:527-534, 2003
19. Munstedt K, Kovacic M, Zygmunt M, et al: Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol 23:837-843, 2003
20. Dunst J, Kuhnt T, Strauss HG, et al: Anemia in cervical cancers: Impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 56:778-787, 2003
21. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
22. Rickels FR, Falanga A: Molecular basis for the relationship between thrombosis and cancer. Thromb Res 102:V215-V224, 2001
23. Sallah S, Wan JY, Nguyen NP: Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb Haemost 87:575-579, 2002
24. Henke M, Laszig R, Rübe C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260, 2003
25. Acs G, Acs P, Beckwith SM, et al: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61:3561-3565, 2001
26. Arcasoy MO, Amin K, Karayal AF, et al: Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82:911-918, 2002
27. Yasuda Y, Fujita Y, Masuda S, et al: Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 23:1797-1805, 2002
28. McBroom JW, Aes G, Rose GS, et al: Erythopoetin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol July 25, 2005 (epub ahead of print)
29. Westenfelder C, Baranowski RL: Erythropoietin stimulates proliferation of human renal cell carcinoma cells. Kidney Int 58:647-657, 2000
30. Acs G, Zhang PJ, Rebbeck TR, et al: Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95:969-981, 2002
31. Batra S, Perelman N, Luck LR, et al: Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83:1477-1487, 2003
32. Dillard DG, Venkatraman G, Cohen C, et al: Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma. Acta Otolaryngol 121:149-152, 2001
33. Selzer E, Wacheck V, Kodym R, et al: Erythropoietin receptor expression in human melanoma cells. Melanoma Res 10:421-426, 2000
34. Westphal G, Niederberger E, Blum C, et al: Erythropoietin and G-CSF receptors in human tumor cells: Expression and aspects regarding functionality. Tumori 88:150-159, 2002
35. Pajonk F, Sommer A, Weil A, et al: Activation of the erythropoietin- receptor pathway does not affect chemo- or radiosensitivity of EpoR expressing cancer cells. Breast Cancer Res Treat 76: S81, 2002 (abstr 286; suppl 1)
36. Olujohungbe A, Handa S, Holmes J: Does erythropoietin accelerate malignant transformation in multiple myeloma? Postgrad Med J 73: 163-164, 1997
37. Falcioni M, Taibah A, De Donato G, et al: Fast-growing vestibular schwannoma. Skull Base Surg 10:95-99, 2000
38. Rizzo D, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107, 2002
39. Sabbatini P, Cella D, Chanan-Khan A, et al: Cancer and treatment-related anemia. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, v. 1.2004. Rockledge, PA: National Comprehensive Cancer Network Inc, January 2004
40. Chang J, Couture F, Young S: Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23:2597-2605, 2005